Dechra launches new canine epilepsy therapy Soliphen

Dechra has announced the UK launch of Soliphen, a new product for the management of canine epilepsy cases.

The tablet-based therapy is designed as a first-line treatment for the condition and contains the antiepileptic ingredient phenobarbital, which has been shown to be well-tolerated and effective as a monotherapy in 60 to 80 percent of dogs with idiopathic epilepsy.

Meanwhile, for the 40 percent of dogs whose epilepsy cannot be controlled with phenobarbital alone, Dechra's potassium bromide-based treatment Libromide is licensed for use alongside Soliphen as a concurrent therapy.

This combination can reduce seizure frequency and severity even in dogs with refractory idiopathic epilepsy, with tests showing that this regimen can cut the mean seizure rate from 27.4 seizures to 2.2 seizures per month.

Craig Sankey, brand manager for Dechra Veterinary Products, said: "We believe using Soliphen as a sole therapy or in conjunction with Libromide will make a positive contribution to veterinary professionals in their ongoing treatment and management of dogs with epilepsy."

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.